Neurocrine Biosciences
NBIX
#1366
Rank
ยฃ11.63 B
Marketcap
ยฃ116.66
Share price
0.84%
Change (1 day)
17.74%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : ยฃ0.94 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are ยฃ0.94 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31ยฃ0.89 B12.44%
2023-12-31ยฃ0.80 B46.47%
2022-12-31ยฃ0.54 B5.57%
2021-12-31ยฃ0.51 B15.92%
2020-12-31ยฃ0.44 B-12.51%
2019-12-31ยฃ0.51 B26.41%
2018-12-31ยฃ0.40 B22.47%
2017-12-31ยฃ0.32 B710%
2016-12-31ยฃ40.69 M19.81%
2015-12-31ยฃ33.96 M54.01%
2014-12-31ยฃ22.05 M6.16%
2013-12-31ยฃ20.77 M-19.3%
2012-12-31ยฃ25.74 M-48.89%
2011-12-31ยฃ50.36 M-37.84%
2010-12-31ยฃ81.02 M96.09%
2009-12-31ยฃ41.31 M-25.61%
2008-12-31ยฃ55.54 M-30.14%
2007-12-31ยฃ79.51 M107.76%
2006-12-31ยฃ38.26 M-29.05%
2005-12-31ยฃ53.94 M-17.41%
2004-12-31ยฃ65.31 M-28.69%
2003-12-31ยฃ91.58 M247.29%
2002-12-31ยฃ26.37 M6.34%
2001-12-31ยฃ24.79 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Repligen
RGEN
ยฃ0.63 B-33.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
ยฃ7.29 B 670.65%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
ยฃ7.58 M-99.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
ยฃ68.32 B 7,116.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
ยฃ102.39 B 10,715.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ86.74 B 9,062.11%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
ยฃ0.67 B-28.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
ยฃ32.87 M-96.53%๐Ÿ‡บ๐Ÿ‡ธ USA